ESTRO 2024 - Abstract Book

S25

Invited Speaker

ESTRO 2024

Challenges in radiopharmaceutical development and evaluation

Freddy E Escorcia

National Cancer Institute, Radiation Oncology Branch, Molecular Imaging Branch, Bethesda, USA

Abstract:

Radiotheranostics have changed how we diagnose and treat human cancers. In search of the elusive cure, the next wave of agents will likely include development of variants of well-known agents to well-known targets, and evaluation of existing agents in earlier lines of treatment or for use in other cancers. However, for the modality to gain a firmer foundation, systematic development of novel agents is needed. Next-generation sequencing datasets of patient tumor samples to identify new therapeutic targets, and increasingly available and economical biomolecule discovery platforms (e.g. phage display, high-throughput screens) can be integrated in existing radiotheranostics labs to achieve these goals. Using hepatocellular carcinoma as a focused disease model, Dr. Escorcia shares work from his lab and beyond and highlights successes and failures in this endeavor.

3313

Challenges in radiopharmaceutical training and workforce

Ana Kiess

Johns Hopkins University, Radiation Oncology, Baltimore, USA

Abstract:

In recent years, [ 177 Lu] Lu-DOTATATE, [ 177 Lu] Lu-PSMA-617 and [ 223 Ra] RaCl 2 have been incorporated into standard of care treatment for patients with advanced neuroendocrine cancers and metastatic castrate-resistant prostate cancer. Furthermore, over 100 other radiopharmaceutical therapy agents are currently in development. This has led to a dramatic increase in workforce demand for authorized physicians and qualified medical physicists, as well as other staff and infrastructure for administration and management of radiopharmaceutical therapies. The projected workforce teams and needs vary across regions, countries, and institutions. There is significant variability in current training, and efforts to standardize include multidisciplinary work from societies, accreditation councils, regulatory agencies and the International Atomic Energy Agency. This session will compare and contrast workforce teams and needs in various regions and provide an overview of several recent training efforts. It will also discuss the roles of radiation oncologists, medical physicists, technologists and other professionals in this evolving and expanding treatment area.

3314

Child-friendly on-treatment solutions (RTT perspective)

Liam Herbert

University Hospital Birmingham, Midlands Paediatric Radiotherapy Service, Birmingham, United Kingdom